Although TRAIL- or Fas ligand-mediated apoptosis-resistant cancer cells have been reported, one option for cancer therapy would combine the anti-tumour effects of TRAIL and Fas ligand with standard chemotherapy58, 59. This evidence concerns the gene TNFSF10 and neoplasm.